- Home
- ETON vs TPVG Comparison
ETON vs TPVG Comparison
Compare ETON & TPVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- TPVG
- Stock Information
- Founded
- ETON 2017
- TPVG 2013
- Country
- ETON United States
- TPVG United States
- Employees
- ETON N/A
- TPVG N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- TPVG Other Consumer Services
- Sector
- ETON Health Care
- TPVG Consumer Discretionary
- Exchange
- ETON Nasdaq
- TPVG Nasdaq
- Market Cap
- ETON 329.8M
- TPVG 296.2M
- IPO Year
- ETON 2018
- TPVG N/A
- Fundamental
- Price
- ETON $14.57
- TPVG $7.06
- Analyst Decision
- ETON Strong Buy
- TPVG Hold
- Analyst Count
- ETON 3
- TPVG 5
- Target Price
- ETON $24.00
- TPVG $7.50
- AVG Volume (30 Days)
- ETON 245.8K
- TPVG 336.5K
- Earning Date
- ETON 05-08-2025
- TPVG 03-05-2025
- Dividend Yield
- ETON N/A
- TPVG 17.01%
- EPS Growth
- ETON N/A
- TPVG N/A
- EPS
- ETON N/A
- TPVG 0.82
- Revenue
- ETON $34,677,000.00
- TPVG $108,208,000.00
- Revenue This Year
- ETON $22.19
- TPVG N/A
- Revenue Next Year
- ETON $109.55
- TPVG $0.42
- P/E Ratio
- ETON N/A
- TPVG $8.59
- Revenue Growth
- ETON 5.64
- TPVG N/A
- 52 Week Low
- ETON $3.03
- TPVG $6.44
- 52 Week High
- ETON $18.41
- TPVG $9.73
- Technical
- Relative Strength Index (RSI)
- ETON 41.13
- TPVG 30.36
- Support Level
- ETON $14.28
- TPVG $7.25
- Resistance Level
- ETON $15.73
- TPVG $7.50
- Average True Range (ATR)
- ETON 0.92
- TPVG 0.20
- MACD
- ETON -0.04
- TPVG -0.09
- Stochastic Oscillator
- ETON 25.19
- TPVG 3.01
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.